Anthony Elias

Active 1986–2025

99
Papers
20,952
Citations
70
h-index
96
i10-index

Citations

Citations per year for Anthony Elias1982: 1 citations1988: 3 citations1989: 22 citations1990: 26 citations1991: 21 citations1992: 41 citations1993: 31 citations1994: 18 citations1995: 52 citations1996: 26 citations1997: 27 citations1998: 19 citations1999: 31 citations2000: 44 citations2001: 14 citations2002: 35 citations2003: 33 citations2004: 25 citations2005: 35 citations2006: 36 citations2007: 39 citations2008: 43 citations2009: 69 citations2010: 87 citations2011: 72 citations2012: 95 citations2013: 87 citations2014: 76 citations2015: 107 citations2016: 105 citations2017: 183 citations2018: 158 citations2019: 507 citations2020: 661 citations2021: 689 citations2022: 594 citations2023: 560 citations2024: 946 citations2025: 454 citations2026: 13 citations1983–1987: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,362 citing papers, 27% of this breakdownChina: 1,120 citing papers, 12.8% of this breakdownItaly: 517 citing papers, 5.9% of this breakdownUnited Kingdom: 461 citing papers, 5.3% of this breakdownGermany: 364 citing papers, 4.2% of this breakdownFrance: 342 citing papers, 3.9% of this breakdownCanada: 310 citing papers, 3.5% of this breakdownSpain: 262 citing papers, 3% of this breakdownNetherlands: 234 citing papers, 2.7% of this breakdownAustralia: 218 citing papers, 2.5% of this breakdownJapan: 215 citing papers, 2.5% of this breakdownBelgium: 203 citing papers, 2.3% of this breakdown
0%27%Other 24.4%

Fields

  • Medicine61.9%
  • Biochemistry, Genetics and Molecular Biology30.1%
  • Immunology and Microbiology2.8%
  • Computer Science1.4%
  • Engineering0.8%
  • Mathematics0.6%
  • Other2.4%

Topics

  • Breast Cancer Treatment Studies7.9%
  • HER2/EGFR in Cancer Research4%
  • Advanced Breast Cancer Therapies3.7%
  • Cancer Immunotherapy and Biomarkers3.7%
  • Cancer Cells and Metastasis3%
  • Cancer Genomics and Diagnostics2.3%
  • Other75.4%

Coauthors

All papers

Open in search
  1. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Erica Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica Young, Jennifer L. Burns, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2022 cited by 964

  2. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Melinda L. Telli, Mei Wei, Kari B. Wisinski, Jessica Young, Kay T. Yeung, Mary A. Dwyer, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2023 cited by 440

  3. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Melinda L. Telli, John H. Ward, Jessica Young, Jennifer L. Burns, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2020 cited by 1,618

  4. openalex_id:w4200350191

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stephen‐John Sammut, Jeremy Thomas, David Cameron, A Graham, Peter S Hall, Lorna Mackintosh, Fang Fan, Andrew K. Godwin, Kelsey Schwensen, Priyanka Sharma, Angela DeMichele, Kimberly Cole, Lajos Pusztai, Mi‐Ok Kim, Laura van ‘t Veer, Laura Esserman, W. Fraser Symmans, Kathi Adamson, Kathy S. Albain, Adam L. Asare, Smita Asare, Ronald Balassanian, Heather Beckwith, Scott Berry, Donald A. Berry, Meredith Buxton, Yunn‐Yi Chen, Beiyun Chen, A. Jo Chien, Jane Yuet Ching Hui, Amy S. Clark, Julia L. Clennell, Brian Datnow, Xiuzhen Duan, Kirsten K. Edmiston, Anthony Elias, Erin D. Ellis, David Euhus, Oluwole Fadare, Michael D. Feldman, Andres Forero‐Torres, Barbara Haley, Hyo S. Han, Shuko Harada, Patricia Haugen, Teresa Helsten, Gillian L. Hirst, Nola M. Hylton, Claudine Isaacs, Kathleen Kemmer, Qamar J. Khan, Laila Khazai, Molly Klein, Gregor Krings, Julie E. Lang, Lauren LeBeau, Brian Leyland‐Jones, Minetta C. Liu, Shelly S. Lo, Janice Lu, Anthony M. Magliocco, Jeffrey B. Matthews, Michelle Melisko, Paulette Mhawech‐Fauceglia, Stacy L. Moulder, Rashmi K. Murthy, Rita Nanda, Donald W. Northfelt, Idris Tolgay Ocal, Olufunmilayo I. Olopade and 28 more cited by 353

  5. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Richard B. Schwab, W. Fraser Symmans, Laura van ‘t Veer, Douglas Yee, Angela DeMichele, Nola M. Hylton, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Donald A. Berry, Laura J. Esserman - JAMA Oncology 2020 cited by 706

  6. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Scott Berry, Ashish Sanil, Adam L. Asare, Jeffrey B. Matthews, Jane Perlmutter, Michelle Melisko, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Douglas Yee, Laura J. van’t Veer, Nola M. Hylton, Angela DeMichele, Donald A. Berry, Laura J. Esserman - Cancer Cell 2021 cited by 330

  7. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, Mei Wei, Kari B. Wisinski, Kay T. Yeung, Jessica Young, Ryan Schonfeld, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2024 cited by 560

  8. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 cited by 221

  9. Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Erica Stringer-Reasor, Anne M. Wallace, Lajos Pusztai, Judy C. Boughey, Erin D. Ellis, Anthony Elias, Janice Lu, Julie E. Lang, Hyo S. Han, Amy S. Clark, Rita Nanda, Donald W. Northfelt, Qamar J. Khan, Rebecca K. Viscusi, David Euhus, Kirsten K. Edmiston, Jane Yuet Ching Hui, Kathleen Kemmer, John W. Park, Minetta C. Liu, Olufunmilayo I. Olopade, Brian Leyland‐Jones, Debasish Tripathy, Stacy L. Moulder, Hope S. Rugo, Richard B. Schwab, Shelly S. Lo, Teresa Helsten, Heather Beckwith, Patricia Haugen, Nola M. Hylton, Laura J. van’t Veer, Jane Perlmutter, Michelle Melisko, Amy Wilson, Garry Peterson, Adam L. Asare, Meredith Buxton, Melissa Paoloni, Julia L. Clennell, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Jeffrey B. Matthews, Smita Asare, Ashish Sanil, Scott Berry, Laura J. Esserman, Donald A. Berry - JAMA Oncology 2020 cited by 225

  10. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update

    Authors: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 129

  11. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 94

  12. Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Barbara Haley, Rita Nanda, Donald W. Northfelt, Debasish Tripathy, William C. Wood, Cheryl A. Ewing, Richard B. Schwab, Julia Lyandres, Sarah Davis, Gillian L. Hirst, Ashish Sanil, Donald A. Berry, Laura J. Esserman - New England Journal of Medicine 2016 cited by 555

  13. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment

    Authors: , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2024 cited by 60

  14. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen

    Authors: , , , , , , , , , , , - Clinical Cancer Research 2016 cited by 234

  15. NCCN Guidelines Insights: Breast Cancer, Version 1.2017

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John H. Ward, Dorothy A. Shead, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2017 cited by 542

  16. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica Young, Jennifer L. Burns, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2021 cited by 351

  17. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kathy S. Albain, Rashmi K. Murthy, Judy C. Boughey, Minetta C. Liu, Barbara Haley, Anthony Elias, Amy S. Clark, Kathleen Kemmer, Claudine Isaacs, Julie E. Lang, Hyo S. Han, Kirsten K. Edmiston, Rebecca K. Viscusi, Donald W. Northfelt, Qamar J. Khan, Brian Leyland‐Jones, Sara J. Venters, Sonal Shad, Jeffrey B. Matthews, Smita Asare, Meredith Buxton, Adam L. Asare, Hope S. Rugo, Richard B. Schwab, Teresa Helsten, Nola M. Hylton, Laura van ‘t Veer, Jane Perlmutter, Angela DeMichele, Douglas Yee, Donald A. Berry, Laura J. Esserman - JAMA Oncology 2021 cited by 106

  18. Adaptive Randomization of Neratinib in Early Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David Euhus, Barbara Haley, Qamar J. Khan, William C. Wood, Michelle Melisko, Richard B. Schwab, Teresa Helsten, Julia Lyandres, Sarah Davis, Gillian L. Hirst, Ashish Sanil, Laura J. Esserman, Donald A. Berry - New England Journal of Medicine 2016 cited by 460

  19. Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Praveen Vikas, Rachel L. Yung, Hope S. Rugo - Journal of Clinical Oncology 2024 cited by 48

  20. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet 2016 cited by 588

  21. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jane Perlmutter, Nola M. Hylton, Laura J. van’t Veer, Angela DeMichele, Amy Wilson, Garry Peterson, Meredith Buxton, Melissa Paoloni, Julia L. Clennell, Scott Berry, Jeffrey B. Matthews, Katherine Steeg, Ruby Singhrao, Gillian L. Hirst, Ashish Sanil, Christina Yau, Smita Asare, Donald A. Berry, Laura J. Esserman - Journal of Clinical Oncology 2020 cited by 112

  22. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John H. Ward, Rashmi Kumar, Dorothy A. Shead - Journal of the National Comprehensive Cancer Network 2018 cited by 1,616

  23. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

    Authors: , , , , , , , , , , , , , , , , , , , - Breast Cancer Research 2014 cited by 432

  24. Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: A Behavioral Weight Loss Intervention in Overweight or Obese Breast Cancer Survivors

    Authors: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 cited by 219